Drugs / NT-I7
NT-I7
also known as
GX-I7 · Efineptakin Alfa · rhIL-7-hyFc · TJ107 · [14C] GX-I7 · Efineptakin-Alpha · IL-7 · interleukin-7 · +1 more
Trials 34 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04781309 | May 2021 → Nov 2025 | progressive multifocal leukoencephalopathy | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 0 | NCT04283695 | Jul → Aug 2019 | leukopenia | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT07200089 | Jun 2026 → Mar 2028 expected | plasma cell myeloma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT07052305 | Mar 2026 → Nov 2027 expected | large B-cell lymphoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT06344715 | Oct 2022 → Oct 2024 | castration-resistant prostate carcinoma | SL VAXiGEN | Unknown | No outcome recorded |
| Phase 1 | NCT04893018 | May 2022 → Dec 2023 | HIV infectious disease, Kaposi's sarcoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT05075603 | Aug 2021 → Dec 2024 | high grade B-cell lymphoma | NeoImmuneTech | Completed | No outcome recorded |
| Phase 1 | NCT04498325 | Jul 2021 → Apr 2022 | COVID-19 | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04730427 | Mar 2021 → May 2022 | COVID-19 | Genexine, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04588038 | Mar 2021 → Feb 2025 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Hyunseok Kang, MD | Terminated | No outcome recorded |
| Phase 1 | NCT04594811 | Jan 2021 → May 2023 | adenocarcinoma | NeoImmuneTech | Terminated | No outcome recorded |
| Phase 1 | NCT04501796 | Nov 2020 → Jul 2021 | COVID-19 | NeoImmuneTech | Terminated | No outcome recorded |
| Phase 1 | NCT02659800 | Oct 2018 → Mar 2022 | lymphopenia, malignant glioma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT03733587 | Oct 2018 → Apr 2020 | cancer | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03619239 | Jun 2018 → Sep 2020 | glioblastoma | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03478995 | Mar 2018 → Mar 2020 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03144934 | Feb 2017 → Mar 2018 | human papilloma virus infection | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02860715 | Jul 2016 → Jan 2017 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT05600920 | Nov 2024 → Nov 2026 expected | idiopathic CD4-positive T-lymphocytopenia | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04332653 | Jun 2020 → Nov 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma, ovarian cancer +2 | NeoImmuneTech | Completed | No outcome recorded |
| Phase 1/2 | NCT03901573 | Dec 2019 → Aug 2023 | cutaneous neuroendocrine carcinoma, melanoma, skin squamous cell carcinoma | NeoImmuneTech | Terminated | No outcome recorded |
| Phase 1/2 | NCT04065087 | Aug 2019 → May 2022 | glioblastoma | Genexine, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03752723 | Mar 2019 → May 2023 | triple-negative breast carcinoma | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04001075 | Feb 2019 → Jun 2021 | high grade malignant neoplasm | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03687957 | Jan 2019 → Feb 2023 overdue | glioma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05465954 | Jan 2023 → Oct 2027 expected | IDH-wildtype glioblastoma, gliosarcoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05280457 | Apr 2022 → Jan 2027 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05286060 | Mar 2022 → Oct 2026 expected | head and neck squamous cell carcinoma | Yonsei University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05191784 | Jan 2022 → Dec 2024 | glioblastoma | Genexine, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05145907 | Dec 2021 → Jun 2024 | head and neck squamous cell carcinoma, triple-negative breast carcinoma | TJ Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04984811 | Nov 2021 → Aug 2024 | non-small cell lung carcinoma | NeoImmuneTech | Terminated | No outcome recorded |
| Phase 2 | NCT04600817 | Dec 2020 → Dec 2024 | glioblastoma | TJ Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04810637 | Nov 2020 → Jun 2021 | COVID-19 | PT Kalbe Genexine Biologics | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03206138 | May 2017 → Oct 2018 | cervical intraepithelial neoplasia grade 2/3 | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04289155 Background | — | glioblastoma, melanoma | Genexine, Inc. | No longer available | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT-I7 | “Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T
Cells and Enhances Survival in Mouse Glioma Models.” PMID 35031547 ↗ Mar 202210“A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia” NCT05600920 ↗ |
| Known as | [14C] GX-I7 | “GX-I7 or [14C] GX-I7” NCT04283695 ↗ |
| Known as | Efineptakin Alfa | “GX-I7 (rhIL-7-hyFc, efineptakin alfa) is a hybrid Fc-fused long-acting interleukin-7 (IL-7) with the aim of correcting T-cell deficiency, thereby strengthening the immune...” PMID 40490502 ↗ Jun 20256“A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia” NCT05600920 ↗ |
| Known as | Efineptakin-Alpha | “Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha)” NCT05600920 ↗ |
| Known as | GX-I7 | “GX-I7 (rhIL-7-hyFc, efineptakin alfa) is a hybrid Fc-fused long-acting interleukin-7 (IL-7) with the aim of correcting T-cell deficiency, thereby strengthening the immune...” PMID 40490502 ↗ Jun 2025 |
| Known as | IL-7 | “NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T cell counts with a well-tolerated safety...” NCT04498325 ↗ |
| Known as | interleukin-7 | “NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T cell counts with a well-tolerated safety...” NCT04498325 ↗ |
| Known as | Long-Acting Recombinant Human Interleukin-7 | “Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.” PMID 35031547 ↗ Mar 2022 |
| Known as | rhIL-7-hyFc | “GX-I7 (rhIL-7-hyFc, efineptakin alfa) is a hybrid Fc-fused long-acting interleukin-7 (IL-7) with the aim of correcting T-cell deficiency, thereby strengthening the immune...” PMID 40490502 ↗ Jun 20252“A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent...” NCT02659800 ↗ |
| Known as | TJ107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05145907 ↗ |
| Modality | Protein / enzyme biologic | “GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc).” NCT02860715 ↗ |
| Route | Intramuscular | “single dose of NT-I7 by intramuscular injection” NCT02659800 ↗ |